Education
About Us
Working with TipRanks
Follow Us
Percheron Therapeutics Limited (PERCF)
:PERCF
Total Valuation
Percheron Therapeutics has a market cap or net worth of $6.40M. The enterprise value is ―.
Market Cap$6.40M
Enterprise Value―
Share Statistics
Percheron Therapeutics has 1,087,437,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,087,437,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Percheron Therapeutics’s return on equity (ROE) is -1.27 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-1.27
Return on Assets (ROA)-0.82
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Percheron Therapeutics is 0.00. Percheron Therapeutics’s PEG ratio is ―.
PE Ratio0.00
PS Ratio0.00
PB Ratio―
Price to Fair Value0.00
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Percheron Therapeutics had revenue of 0.00 and earned -11.92M in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income-11.92M
Net Income-11.92M
EBITDA-11.84M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Percheron Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.14
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)333.00
Important Dates
Percheron Therapeutics upcoming earnings date is Aug 27, 2025, TBA (Confirmed).
Last Earnings DateFeb 19, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date―
Financial Position
Percheron Therapeutics as a current ratio of 2.81, with Debt / Equity ratio of ―
Current Ratio2.81
Quick Ratio2.81
Debt to Market Cap0.00
Net Debt to EBITDA1.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Percheron Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Percheron Therapeutics EV to EBITDA ratio is 1.00, with an EV/FCF ratio of 1.17.
EV to Sales0.00
EV to EBITDA1.00
EV to Free Cash Flow1.17
EV to Operating Cash Flow0.00
Balance Sheet
Percheron Therapeutics has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt―
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share$0.00
Margins
Gross margin is ―, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin―
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Percheron Therapeutics is $0.01, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$0.01
Price Target Upside0.00%
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―